New progress in immune cells characteristics and immunotherapy of chronic myeloid leukemia
10.3969/j.issn.1671-8348.2024.20.023
- VernacularTitle:慢性髓细胞白血病免疫细胞特点与免疫疗法的新进展
- Author:
Shengqiang GELI
1
;
Shu CHEN
;
Xiaodong WANG
;
Jingying DAI
Author Information
1. 电子科技大学附属医院/四川省医学科学院·四川省人民医院血液内科,成都 610072
- Keywords:
chronic myeloid leukemia;
tyrosine kinase inhibitor;
natural killer cell;
T cell;
dendritic cell;
myeloid-derived suppressor cells;
Treg;
review
- From:
Chongqing Medicine
2024;53(20):3173-3178,3183
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia(CML)is a hematological system malignant tumor characterized by the appearance of Ph chromosomes and the formation of BCR-ABL fusion gene.With the emergence of tyrosine kinase inhibitors,the efficacy and survival of CML have been improved significantly.However,there are still some patients with inevitable disease progression and recurrence.In CML patients,the body's own an-ti-tumor immunity can play a role in monitoring,recognizing and eliminating the leukemia cells,which is closely correlated with the occurrence,development,curative efficacy and prognosis of the disease.The immune cells such as natural killer(NK)cells,T cells,dendritic cells,Treg and MDSC play a key role in anti-tumor immunity.Therefore,this article reviews the characteristics of CML immune cells,correlation between the body's own anti-tumor immune status and therapeutic effect,and the recent progress of CML immunotherapy.
